Prof. Markus Joerge - Pharmakologie - Excellence in Innovation
Cantonal Hospital St.Gallen - Switzerland
Author Profile
Early Academic Pursuits
Prof. Markus Jörger's academic journey commenced with his medical training at the University of Basel, Switzerland, where he obtained his medical diploma in November 1996. He delved into various medical specialties, including Internal Medicine and Neurology, before specializing in Medical Oncology. His educational pursuits took him to renowned institutions such as Universitätsspital Zurich and Kantonsspital St. Gallen, where he honed his skills in oncology and hematology. His thirst for knowledge led him to pursue a Ph.D. at Utrecht University in the Netherlands, where he focused on pharmacokinetics and pharmacogenetics in solid cancer patients, further solidifying his expertise in the field.
Professional Endeavors
Prof. Jörger's professional journey has been marked by a series of notable positions and responsibilities. He currently serves as an Attending Medical Oncologist at Kantonsspital St. Gallen, where he provides expert care to cancer patients. Additionally, he holds the esteemed position of Assistant Professor at Basel University, where he imparts knowledge to the next generation of medical professionals. His role as Chair of the Clinical Research Facility at the Department of Medical Oncology & Hematology underscores his commitment to advancing clinical research in oncology. Moreover, his co-presidency of the SAKK Project Group for Developmental Therapeutics demonstrates his leadership in the development of innovative cancer treatments.
Contributions and Research Focus
Prof. Jörger's research focuses on translational oncology, with an emphasis on pharmacology and pharmacogenetics. He has made significant contributions to understanding drug resistance mechanisms in cancer and identifying predictive markers for treatment response. His work has been instrumental in guiding clinical decision-making and improving patient outcomes. Additionally, Dr. Jörger's supervision of numerous master's, M.D., and Ph.D. theses underscores his dedication to nurturing young researchers and advancing scientific knowledge in the field of oncology.
Accolades and Recognition
Throughout his career, Prof. Jörger has received numerous awards and grants in recognition of his outstanding contributions to oncology research. These accolades highlight the impact of his work and the esteem in which he is held by his peers and the scientific community. Notable awards include the Translational Research Fellowship Grant from the Union for International Cancer Control (UICC) and the European Society for Medical Oncology (ESMO), as well as grants from prestigious organizations such as the Swiss National Science Foundation and Krebsforschung Schweiz.
Impact and Influence
Prof. Jörger's work has had a profound impact on the field of oncology, influencing clinical practice and research directions. His research findings have been published in top-tier journals and have been cited extensively, contributing to the collective knowledge base in oncology. Moreover, his role as a peer reviewer for various prestigious journals underscores his influence in shaping the scientific discourse and ensuring the quality of published research.
Legacy and Future Contributions
As a leader in the field of oncology, Prof. Jörger's legacy lies in his significant contributions to translational research and clinical practice. His dedication to mentoring the next generation of researchers ensures that his influence will endure for years to come. Looking ahead, Dr. Jörger remains committed to advancing oncology research and improving patient outcomes through innovative treatments and personalized medicine approaches, cementing his legacy as a pioneer in the field.
Notable Publication
- First-line durvalumab in patients with PD-L1 positive, advanced non-small cell lung cancer (NSCLC) with a performance status of 2 (PS2). Primary analysis of the multicenter, single-arm phase II trial SAKK 19/17 European Journal of CancerThis link is disabled., 2024, Mark, M., Froesch, P., Gysel, K., ...Joerger, M., Früh, M.
- SAKK57/16 Nab-paclitaxel and Gemcitabine in Soft Tissue Sarcoma (NAPAGE): a phase I/II trial European Journal of CancerThis link is disabled., 2024, Digklia, A., Kollár, A., Dietrich, D., ...Ribi, K., Rothermundt, C.
- Phase I/Ib, open-label, multicenter, dose-escalation study of the anti-TGF-β monoclonal antibody, NIS793, in combination with spartalizumab in adult patients with advanced tumors Journal for ImmunoTherapy of CancerThis link is disabled., 2023, Bauer, T.M., Santoro, A., Lin, C.-C., ...Fabre, C., Doi, T.
- Phase 1 first-in-human dose-escalation study of ANV419 in patients with relapsed/refractory advanced solid tumors Journal for ImmunoTherapy of CancerThis link is disabled., 2023, Joerger, M., Calvo, E., Laubli, H., ...Jethwa, S., Garralda, E.
- C-Reactive Protein as an Early Predictor of Efficacy in Advanced Non-Small-Cell Lung Cancer Patients: A Tumor Dynamics-Biomarker Modeling Framework CancersThis link is disabled., 2023, Nassar, Y.M., Ojara, F.W., Pérez-Pitarch, A., ...Joerger, M., Kloft, C.